UroGen Pharma Ltd. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a Q4-only filing; quarterly revenue and profit figures are not provided in the supplied filing text. UroGen is a biopharmaceutical company commercializing Jelmyto and developing therapies for urologic cancers.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $11.8 million | $18,000 |
| Gross profit | $10.8 million; approximately 91% reported gross margin | $18,000 |
| Research and development expense | $47.3 million | $49.3 million |
| Selling and marketing expense | $46.5 million | $17.9 million |
| General and administrative expense | $43.7 million | $42.3 million |
| Operating loss | $126.7 million | $109.5 million |
| Net loss | $128.5 million; $5.90 per share | $105.1 million; $5.12 per share |
| Operating cash flow | $(105.9) million | $(71.0) million |
At year-end, cash and cash equivalents were $52.9 million and marketable securities were $51.0 million, totaling $103.9 million. Current assets were $115.6 million and current liabilities $21.4 million. The balance sheet lists no borrowings or debt. Accumulated deficit was $356.5 million. Management stated existing cash and securities were expected to fund planned operations for at least 12 months, while also anticipating continued losses and a need for additional capital.
Material changes and business developments
- FDA approved Jelmyto for adult patients with low-grade upper tract urothelial cancer (UTUC) in April 2020; U.S. commercial launch began in June. Full-year Jelmyto sales were $11.8 million. The company said some year-end bulk orders reflected concern about holiday shipment delays and did not expect a similar stocking pattern in Q1 2021.
- Operating expenses rose $28.0 million, driven primarily by a $28.6 million increase in selling and marketing costs for the Jelmyto launch. Net loss widened by $23.3 million year over year.
- Cash used in operations increased by $34.9 million. Investing activities provided $93.2 million, mainly reflecting maturities of marketable securities; financing provided $16.5 million, including net ATM proceeds of approximately $15.8 million.
- Reported gross margin was affected by sales of Jelmyto inventory whose manufacturing costs had been expensed before approval. Management estimated margin would have been approximately 86%, rather than 91%, without those previously expensed units.
Outlook, risks and unusual items
- UGN-102 Phase 2b OPTIMA II topline results showed a 65% complete response rate (41 of 63 patients); estimated response durability at 12 months from treatment initiation was 72.5%. The Phase 3 ATLAS trial began in December 2020 and was enrolling patients. Approval and commercial success remain uncertain.
- Jelmyto’s principal commercial risks include physician uptake, reimbursement, safety experience in broader use, and the company’s limited commercialization history. The filing reports a permanent product-specific Medicare J-code effective January 1, 2021 and commercial-plan policies covering more than 150 million lives.
- COVID-19 could disrupt clinical trials, supply, physician access and product use. Management expected vaccination-related healthcare resource demands and patient delays to affect Q1 2021 results; the full-year impact was uncertain.
- The Phase 2 APOLLO trial under the AbbVie collaboration failed to meet its primary endpoint; the company attributed this possibly to BOTOX not adequately permeating the urothelium. The parties continued exploring other RTGel applications.
- Unusual expenses included a $6.6 million payment in 2020 to unwind obligations to the Israeli Innovation Authority. The company recorded $3.4 million of income tax expense and a $2.7 million liability for uncertain tax positions, primarily related to intercompany transfer pricing; accrued interest and penalties were $0.7 million.
- After year-end, UroGen announced a $75 million RTW transaction in March 2021, with future tiered payments based on global net sales of Jelmyto and UGN-102, if approved. This was not year-end cash. The filing also disclosed a $500,000 upfront payment under a January 2021 MD Anderson research collaboration.
- Key risks include dependence on Jelmyto, continued operating losses and financing needs, clinical and regulatory uncertainty, single-source suppliers, competition, reimbursement, intellectual-property protection, and geopolitical or currency risks in Israel. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued an unqualified opinion on the financial statements.
Investor facts to verify
- Jelmyto sales, prescriptions, repeat ordering and the impact of the Q4 bulk purchases on subsequent quarters.
- Cash burn, the timing and terms of the $75 million RTW funding, and the company’s post-transaction liquidity runway.
- ATLAS enrollment, trial design and milestones, and whether UGN-102 can confirm the Phase 2 results.
- Jelmyto’s real-world safety, reimbursement levels and adoption, including any post-marketing updates on response durability.
- Resolution or developments in the uncertain tax positions and continued reliability of supply from single-source vendors.